Results 91 to 100 of about 13,103,023 (178)

Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy : a systematic review

open access: yes, 2010
Background & Aims: Chronic hepatitis B patients are at increased risk for hepatocellular carcinoma (HCC). The effect of medium-term nucleos(t)ide analogue therapy on HCC incidence is unclear; therefore, we systematically reviewed all the data on HCC ...
S. Manolakopulos   +3 more
core   +3 more sources

The impact of antiviral therapy on hepatocellular carcinoma epidemiology

open access: yesHepatic Oncology, 2018
The development of nucleos(t)ide analogs and direct antiviral agents has revolutionized the management of chronic infection with HBV and HCV, respectively.
Massimo Colombo, Ana Lleo
doaj   +1 more source

Comparison of first-year results of tenofovir and entecavir treatments of nucleos(t)ide-naive chronic hepatitis B patients with hepatosteatosis

open access: yes, 2015
Background/Aim: Hepatic steatosis may influence the response to antivirals in chronic hepatitis B patients. This study aimed to compare the efficacy of entecavir and tenofovir in nucleos(t) ide-naive chronic hepatitis B patients with hepatosteatosis ...
Levent Filik   +3 more
core   +1 more source

Clinical utility of entecavir for chronic hepatitis B in Chinese patients

open access: yesDrug Design, Development and Therapy, 2013
Jiyao WangZhongshan Hospital, Fudan University, Shanghai, Key Laboratory of Medical Molecular Virology of MOE/MOH, Shanghai, People’s Republic of ChinaAbstract: The People’s Republic of China has one of the highest rates of hepatitis B virus (
Wang JY
doaj  

Response rates in HBeAg-positive patients (HBV DNA <2000 IU/mL, ALT normalization, HBeAg seroconversion, and combined responses) and HBeAg-negative patients (HBV DNA <2000 IU/mL, ALT normalization, and combined responses) over time (mITT population and mITT patients with available data).

open access: yes, 2020
Patients receiving nucleos(t)ide analogs were considered to be non-responders for HBV DNA endpoints at the respective time points. ALT response includes only patients with elevated ALT at baseline.
Ulrich Alshuth (631963)   +16 more
core   +1 more source

Chronic Hepatitis B In Elite Athletes

open access: yesАрхивъ внутренней медицины
Athletes, as well as other general population groups, are at risk of infection with hepatitis viruses.The aim of the study was to characterise the clinical and virological picture of chronic hepatitis B (CHB) in athletes and to evaluate the efficacy of ...
T. H. Nguyen   +4 more
doaj   +1 more source

The long‐term efficacy of combining nucleos(t)ide analog and low‐dose hepatitis B immunoglobulin on post‐transplant hepatitis B virus recurrence

open access: yes, 2016
BackgroundThe aim of this study was to determine the long-term efficacy of nucleos(t)ide analog (NA) and low-dose hepatitis B immunoglobulin (HBIG) combination treatment for preventing post-transplant hepatitis B virus (HBV ...
güngör, gökhan   +23 more
core   +1 more source

Supplemental Material - EDP-514 in healthy subjects and nucleos(t)ide reverse transcriptase inhibitor-suppressed patients with chronic hepatitis B

open access: yes, 2022
Supplementary Material for EDP-514 in healthy subjects and nucleos(t)ide reverse transcriptase inhibitor-suppressed patients with chronic hepatitis B by Jordan J Feld, Eric Lawitz, Tuan Nguyen, Jacob Lalezari, Tarek Hassanein, Paul Martin, Steven-Huy Han,
Jeanne-Marie Giard (11106191)   +13 more
core   +1 more source

The Risk of Developing Hepatocellular Carcinoma Persists in Chronic Hepatitis B Patients Even After the Long-Term Administration of Nucleos(t)ide Analogs [PDF]

open access: yes
Murai K., Hikita H., Yamada R., et al. The Risk of Developing Hepatocellular Carcinoma Persists in Chronic Hepatitis B Patients Even After the Long-Term Administration of Nucleos(t)ide Analogs. Hepatology Research 55, 1228 (2025); https://doi.org/10.1111/
Doi, Akira   +36 more
core   +1 more source

Home - About - Disclaimer - Privacy